Teva Pharmaceutical Industries Ltd (TEVA) Receives $21.74 Consensus Price Target from Analysts

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has received a consensus rating of “Hold” from the twenty-six ratings firms that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $21.74.

A number of analysts have commented on the stock. Mizuho reiterated a “buy” rating and issued a $28.00 price target on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 16th. Wells Fargo & Co set a $23.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, August 2nd. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, November 1st. Royal Bank of Canada reiterated a “hold” rating and issued a $19.00 price target on shares of Teva Pharmaceutical Industries in a research note on Tuesday, July 31st. Finally, Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday.

In related news, VP Richard Daniell sold 2,488 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total transaction of $58,940.72. Following the transaction, the vice president now directly owns 2,488 shares of the company’s stock, valued at $58,940.72. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Deborah A. Griffin sold 2,376 shares of the firm’s stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total transaction of $56,334.96. Following the transaction, the insider now directly owns 2,376 shares in the company, valued at $56,334.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,531 shares of company stock worth $152,749. 0.43% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in TEVA. Pinnacle Associates Ltd. increased its holdings in Teva Pharmaceutical Industries by 11.0% in the 2nd quarter. Pinnacle Associates Ltd. now owns 22,862 shares of the company’s stock valued at $556,000 after buying an additional 2,272 shares during the period. Daiwa Securities Group Inc. increased its holdings in Teva Pharmaceutical Industries by 7.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 34,183 shares of the company’s stock valued at $736,000 after buying an additional 2,329 shares during the period. ARK Investment Management LLC increased its holdings in Teva Pharmaceutical Industries by 9.2% in the 2nd quarter. ARK Investment Management LLC now owns 30,487 shares of the company’s stock valued at $741,000 after buying an additional 2,561 shares during the period. HPM Partners LLC increased its holdings in Teva Pharmaceutical Industries by 25.4% in the 2nd quarter. HPM Partners LLC now owns 14,657 shares of the company’s stock valued at $356,000 after buying an additional 2,971 shares during the period. Finally, Point View Wealth Management Inc. increased its holdings in Teva Pharmaceutical Industries by 4.4% in the 2nd quarter. Point View Wealth Management Inc. now owns 71,603 shares of the company’s stock valued at $1,741,000 after buying an additional 2,996 shares during the period. 65.10% of the stock is currently owned by institutional investors and hedge funds.

Shares of TEVA stock opened at $23.73 on Monday. The firm has a market capitalization of $23.48 billion, a price-to-earnings ratio of 6.04, a PEG ratio of 7.08 and a beta of 0.77. The company has a quick ratio of 0.61, a current ratio of 0.94 and a debt-to-equity ratio of 1.75. Teva Pharmaceutical Industries has a one year low of $11.41 and a one year high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, November 1st. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.53 by $0.11. The firm had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.54 billion. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The company’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.00 earnings per share. As a group, equities research analysts predict that Teva Pharmaceutical Industries will post 2.78 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Investing strategies using the yield curve

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply